Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Deciphering the Insights of Poly(ADP‐Ribosylation) in Tumor Progression

Deciphering the Insights of Poly(ADP‐Ribosylation) in Tumor Progression Poly (ADP‐ribose) polymerase (PARP) inhibitors are particularly efficient against tumors with defects in the homologous recombination repair pathway. Nonetheless poly(ADP‐ribosylation) (PARylation) modulates prometastasic activities and adaptation of tumor to a hostile microenvironment. Modulation of metastasis‐promoting traits is possible through the alteration of key transcription factors involved in the regulation of the hypoxic response, the recruitment of new vessels (or angiogenesis), and the stimulation of epithelial to mesenchymal transition (EMT). In this review, we summarized some of the findings that focalize on PARP‐1's action on tumor aggressiveness, suggesting new therapeutic opportunities against an assembly of tumors not necessarily bearing DNA repair defects. Metastasis accounts for the vast majority of mortality derived from solid cancer. PARP‐1 is an active player in tumor adaptation to metastasis and PARP inhibitors, recognized as promising therapeutic agents against homologous recombination deficient tumors, has novel properties responsible for the antimetastatic actions in different tumor settings. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Medicinal Research Reviews Wiley

Deciphering the Insights of Poly(ADP‐Ribosylation) in Tumor Progression

Download PDF
20 pages

Loading next page...
 
/lp/wiley/deciphering-the-insights-of-poly-adp-ribosylation-in-tumor-progression-8Ytx7t8hBv

References (108)

Publisher
Wiley
Copyright
Copyright © 2015 Wiley Periodicals, Inc.
ISSN
0198-6325
eISSN
1098-1128
DOI
10.1002/med.21339
pmid
25604534
Publisher site
See Article on Publisher Site

Abstract

Poly (ADP‐ribose) polymerase (PARP) inhibitors are particularly efficient against tumors with defects in the homologous recombination repair pathway. Nonetheless poly(ADP‐ribosylation) (PARylation) modulates prometastasic activities and adaptation of tumor to a hostile microenvironment. Modulation of metastasis‐promoting traits is possible through the alteration of key transcription factors involved in the regulation of the hypoxic response, the recruitment of new vessels (or angiogenesis), and the stimulation of epithelial to mesenchymal transition (EMT). In this review, we summarized some of the findings that focalize on PARP‐1's action on tumor aggressiveness, suggesting new therapeutic opportunities against an assembly of tumors not necessarily bearing DNA repair defects. Metastasis accounts for the vast majority of mortality derived from solid cancer. PARP‐1 is an active player in tumor adaptation to metastasis and PARP inhibitors, recognized as promising therapeutic agents against homologous recombination deficient tumors, has novel properties responsible for the antimetastatic actions in different tumor settings.

Journal

Medicinal Research Reviews – Wiley

Published: Jul 1, 2015

There are no references for this article.